Health Care & Life Sciences » Pharmaceuticals | Knight Therapeutics Inc.

Knight Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
-
425
482
766
749
696
Total Accounts Receivable
-
3
16
32
49
20
Inventories
-
1
1
1
1
1
Other Current Assets
-
-
-
1
-
-
Total Current Assets
-
429
499
800
799
718
Net Property, Plant & Equipment
-
-
-
-
1
1
Total Investments and Advances
-
21
111
117
168
270
Long-Term Note Receivable
-
36
32
54
21
20
Intangible Assets
-
1
3
14
13
17
Total Assets
-
487
649
991
1,006
1,052
Accounts Payable
-
-
1
1
1
Income Tax Payable
-
4
4
6
8
Other Current Liabilities
-
3
3
3
6
Total Current Liabilities
-
8
7
10
14
Deferred Taxes
-
-
2
6
5
Other Liabilities
-
-
-
1
1
Total Liabilities
-
8
7
11
15
Common Equity (Total)
-
479
642
980
991
Total Shareholders' Equity
-
479
642
980
991
Total Equity
-
479
642
980
991
Liabilities & Shareholders' Equity
-
487
649
991
1,006

About Knight Therapeutics

View Profile
Address
3400, de Maisonneuve Boulevard West
Montréal Québec H3Z 3B8
Canada
Employees -
Website http://www.gud-knight.com
Updated 07/08/2019
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.